REVENUE (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Net Revenue

The following table reflects summary revenue, net for the three months ended March 31, 2023 and 2022 (in thousands): 

	Three Months Ended March 31,
	2023		2022
Product sales, net:
INDOCIN products	$	30,346	$	21,357
Otrexup	2,822		3,078
Sympazan	2,502		—
SPRIX	1,889		1,766
CAMBIA	2,264		5,473
Zipsor	1,150		2,228
Other products	796		1,644
Total product sales, net	41,769		35,546
Royalties and milestone revenue	697		992
Total revenues	$	42,466	$	36,538